Search PubMed⌕ Search

Biomedical subjects

P Lillsunde

Publications and source records attributed to P Lillsunde.

22 records · Page 2Linked to original sources

Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients.

The combination of carbamazepine and an antidepressant (doxepin, amitriptyline, mianserin) was given to 22 psychiatric inpatients with 29 measurements of their serum antidepressant concentrations. For comparison, sex-, age-, and dose-matched inpatients, treated with the antidepressant but not with carbamazepine, were selected as controls (N = 29). All the patients were treated with their routine daily dose for at least 7 days before the gas-chromatographic measurement of serum predose concentrations of the antidepressants. In patients with carbamazepine, serum doxepin and doxepin + nordoxepin concentrations (N = 17) were decreased significantly (p less than 0.05), on average to 46% and 45%, respectively, as compared to that in subjects without carbamazepine. Also in carbamazepine + amitriptyline patients, serum nortriptyline and amitriptyline + nortriptyline concentrations (N = 8) were significantly lower than in those not receiving carbamazepine (p less than 0.05). The mean serum antidepressant levels were decreased to 42% and 40%, respectively. The serum mianserin concentration of carbamazepine patients (N = 4) was reduced to 30% of that in patients not treated with carbamazepine (p less than 0.01). The percentage fractions of demethylated metabolites (nordoxepin, nortriptyline) from the total antidepressant levels were not influenced by carbamazepine. In patients treated with carbamazepine, serum total antidepressant concentrations remained more often below the suggested therapeutic ranges than in those patients without carbamazepine. The results suggest that serum antidepressant concentrations are reduced by concurrent carbamazepine therapy, and that the concentrations should be carefully monitored when carbamazepine is added to the antidepressant regimen.

Adult↗

Simultaneous screening and quantitative analysis of benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection.

A rapid twin-column gas chromatographic method for the simultaneous screening and determination of commonly prescribed benzodiazepines from plasma and whole blood is presented. Identical fused-silica SE-54 columns were inserted in a common split-splitless injector and connected to nitrogen-phosphorus and electron-capture detectors. By combining these specific and sensitive detectors considerable and accurate chromatographic information was obtained in a single run. The drugs were extracted from 1 ml of buffered plasma or blood with n-hexane-dichloromethane (70:30) and analysed without derivatization. Flurazepam was used as internal standard. The method was reproducible enough to permit reliable quantitation of plasma diazepam, nordiazepam, oxazepam, lorazepam, chlordiazepoxide, temazepam, midazolam, alprazolam, clobazam, norclobazam, adinazolam, flunitrazepam, bromazepam, triazolam, nitrazepam and clonazepam within 12 min.

Benzodiazepines↗

Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification.

A simple and sensitive identification system for the detection of a broad spectrum of drugs is described. ChemElut extraction tubes were used for isolation of drugs from urine. Specimens were screened by thin-layer chromatography (TLC) and confirmed by gas chromatography/mass spectrometry (GC/MS). Special procedures for buprenorphine, cannabinoids, cocaine, LSD, morphine, phencyclidine, halogenated hydrocarbons, paracetamol, and alcohols were used. This system is useful for screening samples in misuse, impaired driving, poisoning, and other forensic cases. It covers about 300 substances including all potentially abused drugs and their metabolites.

Chromatography, Thin Layer↗

Comparison of RapiTest with Emit d.a.u. and GC-MS for the analysis of drugs in urine.

Results obtained with RapiTest THC (One Step delta 9-Tetrahydrocannabinol Test), RapiTest MOP (One Step Morphine Test), RapiTest MET (One Step Methamphetamine Test), and RapiTest COC (One Step Cocaine Test) were compared with the results obtained with Emit d.a.u. and with gas chromatographic-mass spectrometric (GC-MS) methods. In all, 81 urine samples taken from specimens submitted for routine analysis in the Laboratory of Pharmacology and Toxicology were analyzed. Samples were screened with Emit, reanalyzed by RapiTests, and quantitated using GC-MS methods. Both positive and negative urine samples were tested. The results obtained with RapiTests correlated well with the Emit d.a.u. and GC-MS data when operating above the cutoff concentrations specified for these methods. RapiTest MOP was found to have crossreactivity with codeine and ethylmorphine, and RapiTest MET crossreacted with amphetamine.

Cannabinoids↗